Anteris Technologies says Medtronic will make a strategic investment of up to $90 million in the transcatheter heart valve ...

Medtronic’s investment is contingent on Anteris completing a proposed $200 million public stock offering.

The Medtronic investment and the underwritten public offering of common stock position Anteris to continue to execute the global PARADIGM Trial and to continue investing in research that can transform ...

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) announced today that the U.S. Food and Drug Administration (FDA) has approved its transcatheter aortic valve replacement (TAVR) therapy ...

Medtronic will invest $90M in Anteris Technologies for DurAVR TAVR device development, contingent on a $200M IPO.

The global TAVR embolic protection market is experiencing steady growth, with revenue estimated to increase from approximately $124 million in 2023 to around $403 million by 2032. This growth, driven ...

A federal judge has paused the merger of the only two companies developing a heart device made for high-risk patients suffering from ...

St. Luke’s Medical Center - Global City marks a significant milestone for its cardiovascular services, having successfully ...

Could hemolytic anemia be related to the new sealing skirt on the valve?

While many people fear a cancer diagnosis above all else, clinical data reveals that symptomatic aortic stenosis, a severe ...

Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...